Autologous Platelet-Rich Plasma: A Potential Therapy to Mitigate Severe Covid-19 Manifestations

The Chinese Ministry of Health's Chinese Health Protection Centers reported the appearance of COVID-19, a group of pneumonia, in Wuhan toward the end of 2019. Common symptoms found are sore throat, headache, pain, diarrhea, skin lesions, and eye irritation. The immune regulatory system may become dysfunctional as a result of SARS-COV-2, leading to an uncontrolled inflammatory response. These events will then result in lymphocyte activation and dysfunction, lymphopenia, an increase in pro-inflammatory cytokine productions, and abnormalities in granulocytes and monocytes, all of which are symptoms of cytokine release syndrome (CRS). CRS may result in shock, acute respiratory distress syndrome, organ failure, respiratory failure, and even death in COVID-19 patients. In order to avoid this, activated autologous platelet-rich plasma (aaPRP) therapy was created to treat CRS. aaPRP therapy is replicable in a short time, easy, and at a low cost. The numerous growth factors in aaPRP have anti-inflammatory properties that reduce the production of IL-1, IL-6, and TNF. The use of aaPRP treatment may lessen the need for invasive mechanical breathing, avoid alopecia and sepsis, and lessen pulmonary fibrosis. According to the findings of the phase I/II study that were conducted, it shows that aaPRP was given through intravenously and did not cause side effects in COVID-19 patients. To fully comprehend the aaPRP treatment for COVID-19 patients, however, more research is required. This review will go into discuss about the pathophysiology of COVID-19 as well as potential areas for aaPRP therapy.